Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression (vol 104, pg 1202, 2019)

    Thumbnail
    Citations
    Scopus
    Web of Science
    Altmetric
    3
    3
    Author
    Seymour, JF; Marcus, R; Davies, A; Gallop-Evans, E; Grigg, A; Haynes, A; Herold, M; Illmer, T; Nilsson-Ehle, H; Soekler, M; ...
    Date
    2020-05-01
    Source Title
    Haematologica: the hematology journal
    Publisher
    FERRATA STORTI FOUNDATION
    University of Melbourne Author/s
    Seymour, John; Grigg, Andrew
    Affiliation
    Medicine (Austin & Northern Health)
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Seymour, J. F., Marcus, R., Davies, A., Gallop-Evans, E., Grigg, A., Haynes, A., Herold, M., Illmer, T., Nilsson-Ehle, H., Soekler, M., Duenzinger, U., Nielsen, T., Launonen, A. & Hiddemann, W. (2020). Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression (vol 104, pg 1202, 2019). HAEMATOLOGICA, 105 (5), pp.1465-1465. https://doi.org/10.3324/haematol.2020.246991.
    Access Status
    Access this item via the Open Access location
    URI
    http://hdl.handle.net/11343/254194
    DOI
    10.3324/haematol.2020.246991
    Open Access URL
    Published version

    Export Reference in RIS Format     

    Collections